

**Selective activation of tumour necrosis  
factor receptor-mediated intracellular  
signalling pathways**

**VIOLET RUDO SAMANTHA MUKARO**

*(B. Lab. Med. with Hons)*

Thesis submitted for the degree of Doctor of Philosophy

Department of Immunopathology

Children, Youth and Women's Health Service

Faculty of Health Sciences

Discipline of Paediatrics

The University of Adelaide

February 2009

## TABLE OF CONTENTS

<b>Summary .....</b>	<b>ix</b>
<b>Declaration .....</b>	<b>xi</b>
<b>Acknowledgements .....</b>	<b>xii</b>
<b>Publications, presentations and awards.....</b>	<b>xiv</b>
<b>Abbreviations .....</b>	<b>xvii</b>
<b>Index of Figures .....</b>	<b>xxii</b>
<b>Index of Tables.....</b>	<b>xxvi</b>
<b>1.0 Chapter One: Introduction.....</b>	<b>1</b>
<b>1.1 General introduction.....</b>	<b>2</b>
<b>1.2 Neutrophils and inflammation .....</b>	<b>7</b>
1.2.1 Functional cell surface receptors and phagocytosis .....	9
1.2.2 Neutrophil microbicidal mechanisms .....	11
1.2.2.1 Non-oxidative mechanisms .....	13
1.2.3 Oxygen dependent mechanisms.....	13
1.2.4 Neutrophils as a source of cytokines and chemokines.....	17

1.2.5	Role in adaptive immunity.....	19
<b>1.3</b>	<b>Monocytes/macrophages.....</b>	<b>22</b>
1.3.1	Origin and activation of macrophages .....	23
1.3.2	Functional surface receptors on mononuclear phagocytes.....	26
1.3.3	Antimicrobial function.....	26
<b>1.4</b>	<b>Inflammatory mediators.....</b>	<b>28</b>
1.4.1	Arachidonic acid-derived mediators.....	28
1.4.2	Complement .....	29
1.4.3	Nitric oxide (NO).....	30
1.4.4	Cytokines.....	31
<b>1.5</b>	<b>Tumour necrosis factor (TNF).....</b>	<b>36</b>
1.5.1	Regulation of TNF expression.....	37
1.5.2	Biology of TNF .....	38
1.5.3	Pathophysiologic actions of TNF .....	41
<b>1.6</b>	<b>TNF receptors.....</b>	<b>45</b>
1.6.1	TNFR I and TNFR II mediated signalling.....	46
1.6.2	TNFR adaptor proteins .....	48
<b>1.7</b>	<b>Signalling pathways activated by TNF.....</b>	<b>50</b>
1.7.1	Activation of NF- $\kappa$ B.....	50
1.7.2	Activation of sphingomyelinase-ceramide by TNFR I.....	52
1.7.3	Activation of sphingosine kinase by TNF .....	54
1.7.4	Activation of MAPK .....	55
1.7.4.1	Extracellular-signal-regulated kinase (ERK) .....	55
1.7.4.2	c-Jun NH <sub>2</sub> -terminal kinases (JNK).....	57
1.7.4.3	p38 kinase .....	58
1.7.4.4	Summary .....	60

<b>1.8</b>	<b>Targeting TNF-TNFR in pathogenesis .....</b>	<b>61</b>
1.8.1	Anti-TNF antibodies and soluble TNF receptors.....	63
1.8.2	Anti-TNF therapy: shortcomings and failures .....	65
<b>1.9</b>	<b>Targeting intracellular signalling molecules in inflammatory diseases.....</b>	<b>71</b>
<b>1.10</b>	<b>Cytokine mimetics as therapeutics.....</b>	<b>73</b>
<b>1.11</b>	<b>Rationale, aims and hypothesis .....</b>	<b>78</b>
1.11.1	Hypotheses.....	78
1.11.2	Aims.....	79
<b>2.0</b>	<b>Chapter two: Materials and methods .....</b>	<b>80</b>
<b>2.1</b>	<b>Reagents .....</b>	<b>81</b>
2.1.1	Biochemicals and antibodies .....	81
2.1.2	Plasmids.....	82
<b>2.2</b>	<b>Animals.....</b>	<b>82</b>
<b>2.3</b>	<b>Cytokines and peptides .....</b>	<b>82</b>
2.3.1	Cytokines and receptors.....	82
2.3.2	Peptides.....	83
<b>2.4</b>	<b>Purification of human leukocytes.....</b>	<b>84</b>
2.4.1	Purification of peripheral mononuclear cells and neutrophils from whole blood.....	84
2.4.2	Production of TNF-rich medium (TNF-RM) culture fluids.....	85
<b>2.5</b>	<b>Cell lines and their maintenance .....</b>	<b>86</b>
2.5.1	WEHI-164 .....	86
2.5.2	HEK 293T .....	86
2.5.3	Mono Mac 6 cells .....	87
2.5.4	Pre B-cell line 70Z/3.....	87

2.5.4.1	Transfection .....	87
2.5.5	Endothelial cell culture .....	88
<b>2.6</b>	<b>Construction of TNFRI mutants .....</b>	<b>88</b>
<b>2.7</b>	<b>Solid-phase ligand binding assay .....</b>	<b>89</b>
<b>2.8</b>	<b>Activation of intracellular signalling molecules .....</b>	<b>90</b>
2.8.1	Preparation of cell lysates .....	90
2.8.2	Lowry's protein assay .....	90
2.8.3	ERK and p38 activity .....	91
2.8.4	JNK assay .....	92
2.8.5	Measurement of NF- $\kappa$ B activation .....	93
<b>2.9</b>	<b>Cytotoxicity assay .....</b>	<b>94</b>
<b>2.10</b>	<b>Chemiluminescence assay .....</b>	<b>95</b>
<b>2.11</b>	<b>Measurement of CR3 Expression .....</b>	<b>95</b>
<b>2.12</b>	<b>Analysis of cytokine and chemokine gene expression by quantitative real-time PCR .....</b>	<b>96</b>
2.12.1	Isolation of total RNA .....	96
2.12.2	Synthesis of cDNA (Reverse Transcription) .....	97
2.12.3	Quantitative real-time PCR .....	97
<b>2.13</b>	<b><i>In vivo</i> models of inflammation .....</b>	<b>98</b>
2.13.1	Lipopolysaccharide-induced peritoneal inflammation .....	98
2.13.2	Delayed-type hypersensitivity .....	99
2.13.3	Carrageenan-induced paw inflammation .....	99
<b>2.14</b>	<b>Statistics and analysis .....</b>	<b>100</b>
<b>3.0</b>	<b>Chapter three: TNF<sub>70-80</sub> acts through TNF-receptors .....</b>	<b>101</b>

<b>3.1</b>	<b>Introduction .....</b>	<b>102</b>
<b>3.2</b>	<b>TNF<sub>70-80</sub> stimulates p38 activation through TNFRI.....</b>	<b>102</b>
<b>3.3</b>	<b>TNF<sub>70-80</sub> binds to TNFRI.....</b>	<b>103</b>
<b>3.4</b>	<b>Summary .....</b>	<b>108</b>
<b>4.0</b>	<b>Chapter four: The selective activation of TNFRI-induced intracellular signalling pathways by TNF<sub>70-80</sub> and TNF<sub>132-150</sub> .....</b>	<b>109</b>
<b>4.1</b>	<b>Introduction .....</b>	<b>110</b>
<b>4.2</b>	<b>Activation of NFκB pathway by TNF<sub>70-80</sub> .....</b>	<b>111</b>
<b>4.3</b>	<b>Ability of TNF<sub>70-80</sub> to recruit adaptor proteins.....</b>	<b>113</b>
4.3.1	TNF <sub>70-80</sub> stimulates p38 activity via TRAF2.....	113
4.3.2	Lack of activation of germinal centre kinase (GCK), an upstream kinase in the JNK pathway 115	
4.3.3	Lack of activation of ASK-1 by TNF <sub>70-80</sub> .....	115
<b>4.4</b>	<b>Effect of TNF<sub>132-150</sub> on MAPK activation in WEHI-164 cells.....</b>	<b>119</b>
<b>4.5</b>	<b>Summary .....</b>	<b>126</b>
<b>5.0</b>	<b>Chapter five: Identification of the TNF<sub>70-80</sub> binding region and generation of peptides to these regions .....</b>	<b>128</b>
<b>5.1</b>	<b>Introduction .....</b>	<b>129</b>
<b>5.2</b>	<b>Construction of TNFRI mutants .....</b>	<b>130</b>
<b>5.3</b>	<b>The effect of HM4 on TNF<sub>70-80</sub>-induced superoxide production in neutrophils.....</b>	<b>135</b>
<b>5.4</b>	<b>The effect of -HM4 on TNF<sub>70-80</sub>-induced superoxide production in neutrophils.....</b>	<b>138</b>

<b>5.5</b>	<b>The effect of TNFRI<sub>209-211</sub> on TNF-induced superoxide production in neutrophils.....</b>	<b>141</b>
<b>5.6</b>	<b>The effect of TNFRI<sub>206-211</sub> on TNF-induced superoxide production in neutrophils.....</b>	<b>145</b>
<b>5.7</b>	<b>The effect of TNFRI<sub>209-211</sub> and TNFRI<sub>206-211</sub> on the ability of cytokine containing MNL conditioned medium to stimulate neutrophil superoxide production .....</b>	<b>148</b>
<b>5.8</b>	<b>Effect of TNFRI<sub>209-211</sub> and TNFRI<sub>206-211</sub> on fMLP-induced superoxide production in neutrophils.....</b>	<b>152</b>
<b>5.9</b>	<b>Effect of TNFRI<sub>206-211</sub> and TNFRI<sub>209-211</sub> on TNF-induced p38 activation .....</b>	<b>155</b>
<b>5.10</b>	<b>Effect of TNFRI<sub>206-211</sub> on CR3 (CD11b/CD18) expression .....</b>	<b>160</b>
<b>5.11</b>	<b>Effect of TNFRI<sub>206-211</sub> on TNF-induced cytokine production in neutrophils.....</b>	<b>164</b>
5.11.1	Effect of TNFRI <sub>206-211</sub> on TNF-induced IL-1 $\beta$ production .....	164
5.11.2	Effect of TNFRI <sub>206-211</sub> on TNF-induced IL-8 production.....	165
<b>5.12</b>	<b>Effect of the D-amino form of TNFRI<sub>206-211</sub> and other variants of TNFRI on TNF-induced superoxide production.....</b>	<b>172</b>
<b>5.13</b>	<b>Summary .....</b>	<b>177</b>
<b>6.0</b>	<b>Chapter Six: Effects of TNFRI-derived peptides on inflammation .....</b>	<b>180</b>
<b>6.1</b>	<b>Introduction .....</b>	<b>181</b>
<b>6.2</b>	<b>The effect of TNFRI<sub>206-211</sub> on a murine model of acute LPS-induced peritonitis.....</b>	<b>182</b>
<b>6.3</b>	<b>The effect of TNFRI<sub>206-211</sub> on carrageenan-induced paw swelling.....</b>	<b>188</b>
<b>6.4</b>	<b>The effect of TNFRI<sub>206-211</sub> on antigen-induced delayed type hypersensitivity .....</b>	<b>191</b>
<b>6.5</b>	<b>Summary .....</b>	<b>193</b>

<b>7.0</b>	<b>Chapter Seven: Discussion.....</b>	<b>194</b>
<b>7.1</b>	<b>Interaction of TNF<sub>70-80</sub> with the TNFRI .....</b>	<b>195</b>
<b>7.2</b>	<b>Selective activation of MAPK pathways.....</b>	<b>197</b>
<b>7.3</b>	<b>TNF<sub>70-80</sub> binding region- identification of a TNF antagonist .....</b>	<b>202</b>
7.3.1	Structural modification to TNFRI derived peptides .....	205
<b>7.4</b>	<b>Anti-inflammatory properties of TNFRI derived peptides.....</b>	<b>209</b>
<b>7.5</b>	<b>The therapeutic potential of TNFRI derived peptides .....</b>	<b>214</b>
<b>7.6</b>	<b>Peptides as viable therapeutics.....</b>	<b>218</b>
<b>7.7</b>	<b>Concluding remarks.....</b>	<b>221</b>
	<b>References.....</b>	<b>223</b>



## Summary

Tumour necrosis factor (TNF) is a pleiotropic cytokine that has been shown to play a major role in defence against infections and malignancy, and regulation of the innate and adaptive immune responses. Despite its beneficial role, the cytokine has been implicated in the pathophysiology of a range of diseases including sepsis, cerebral malaria and autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. While blocking the activity of excessive TNF has become a therapeutic approach to managing patients with these diseases, there are concerns since this also decreases resistance against infection and cancer. Attempts to target intracellular signalling pathways used by TNF, such as the p38 mitogen activated protein kinase (MAPK) have also met with limitations and studies have been discontinued due to toxicity. Since most proteins exert their biological activity through the interaction between very small regions of their folded surfaces to their cognate receptors, smaller peptides which mimic the shape of the proteins at these points of contact with the receptors can be used to mimic and/or block the actions of these proteins. We have previously demonstrated that the TNF mimetic peptides TNF<sub>70-80</sub> and TNF<sub>132-150</sub> exhibited distinct biological activities, which in combination represented the spectrum of biological activities displayed by TNF. Research in this thesis sought to use these properties to develop new targets for development of anti-inflammatory agents. The mimetic TNF<sub>70-80</sub> was shown to bind and act as a ligand for the TNF receptor I (TNFRI) and selectively activated the p38 MAPK pathway, and not the c-Jun NH<sub>2</sub>-terminal kinase (JNK) and extracellular-signal-regulated kinase 1 and 2 (ERK1/ERK2) pathways. In contrast TNF<sub>132-150</sub> selectively activated the JNK and ERK1/ERK2 pathways. This is consistent with the biological properties of

these peptides. The basis for the activation of a restricted signalling pathway by TNF<sub>70-80</sub> was related to a reduced capability to recruit adapter proteins. The peptide mimetic ligated TNFR was able to functionally couple TNF receptor associated factor 2 (TRAF2) to the p38 and NF- $\kappa$ B pathway but was unable to effect the coupling of germinal centre kinase (GCK) and apoptosis signal-regulating kinase (ASK1) to TRAF2, probably explaining the lack of activation of JNK and ERK1/ERK2 pathways. Using the ability of TNF<sub>70-80</sub> to activate p38, we identified the region to which TNF<sub>70-80</sub> binds to the TNFRI. Synthetic peptides representing the 206-211 amino acid residues of the TNFRI were made and examined for anti-TNF effects *in vitro* and *in vivo*. These TNFR mimetic peptides were found to selectively block TNF induced p38 activation and associated functions of neutrophil superoxide production, CD11b upregulation and cytokine production. Similar results were found with the monocytic cell line, Mono Mac 6. These TNFRI-derived peptides were found to inhibit leukocyte infiltration into inflammatory sites in acute and chronic inflammation models. Our findings open new opportunities for the development of therapeutics which selectively target the TNFR-p38 signalling pathway in chronic inflammatory diseases.

## Declaration

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

.....

Violet R.S. Mukaro

.....

Date

## Acknowledgements

First foremost, I would like to thank my supervisor Professor Antonio Ferrante and my co-supervisor Associate Professor Charles Hii for their, unending guidance, support and dedication throughout my candidacy. I am deeply indebted to them, their encouragement, advice and friendship which have helped me to achieve my best and continue to improve to become a successful researcher.

I would like to thank Dr Sophia Gao and Dr George Mayne for their assistance with the TNFR constructs and signalling studies on the TNFR adapter proteins respectively.

I would like to thank the department of Immunopathology, who over the years have become my home away from home. I would like to thank the diagnostic staff: Trish, Kathie, Jess, Lily, Renee and Tuyen for the assistance and friendship. I would also like to extend warm thanks to the following: Christos, Yong, Bernadette (BM), Mei, Alex and Michelle (Ponch) for your advice, patience with all my questions and most importantly for your friendship over the years. I would also like to especially thank Alex for helping me with the molecular and flow cytometry in my early days.

I would like to thank my friends, both in Adelaide and abroad who have been there through all my many moods of my PhD, special thanks to Claire, Tino, Rumbi, Lungisa, Kelly, Kudzai and Kate. I would also like to thank Virginia and Gloria who have been the perfect 'vana sisi', thank you for the support.

Finally, I would like to extend warm thanks to my family: my parents, Kumbi, Mandifadza, and Michelle, for their endless support and encouragement over the years. This would not be possible in fact impossible without you guys.

## Publications, presentations and awards

### Publications

1. Mukaro, V. R., M. Costabile, K. J. Murphy, C. S. Hii, P. R. Howe, and A. Ferrante. 2008. Leukocyte numbers and function in subjects eating n-3 enriched foods: selective depression of natural killer cell levels. *Arthritis Res Ther* 10 (3): R57.
2. Marantos, C., V. Mukaro, J. Ferrante, C. Hii, and A. Ferrante. 2008. Inhibition of the Lipopolysaccharide-Induced Stimulation of the Members of the MAPK family in Human Monocytes/Macrophages by 4-Hydroxynonenal, a Product of Oxidized Omega-6 Fatty Acids. *Am J Pathol.* 173(4):1057-66.
3. Mukaro, V., X. Gao, C. Haddad, G. Mayne, H. Sundqvist, R. Flower, Z. H Huang, C. S. T. Hii, and A. Ferrante. 2008. Selective signaling via p38 MAP kinase by the TNF peptide mimetic TNF<sub>70-80</sub> involving the TNF receptor. In preparation.
4. Yeh, M, V. Mukaro, C. Marantos, C. Hii and A. Ferrante. 2008. Regulation of neutrophil chemotaxis and phagocytosis by c-jun NH2 terminal kinases. Submitted.

5. Thathaisong, U., V. Mukaro, C. Marantos, C. S. T. Hii, A. Ferrante and N. N. Gorgani. 2008. Arachidonic Acid Inhibits Complement Receptor Immunoglobulins (CRIg) mRNA Expressed During Human Monocytes Maturation to Macrophages and a Role of Protein Kinase C. In preparation.

### **Abstracts presented at conferences**

1. Mukaro, V., Z. Huang, X. Gao, C. Haddad, G. Mayne, H. Sundqvist, R. Flower, C. S. T. Hii, and A. Ferrante. Selective activation of tumour necrosis factor receptor-mediated intracellular signaling pathways. Australian Society for Medical Research Week, SA Scientific Meeting, Adelaide, Australia June 4 2008.
2. Mukaro, V., Z. Huang, X. Gao, C. Haddad, G. Mayne, H. Sundqvist, R. Flower, C. S. T. Hii, and A. Ferrante. Selective activation of TNFR-induced intracellular signalling. Cambridge Healthtech Institute's 15th International Molecular Medicine Tri-Conference. San Francisco, CA, USA March 25-28, 2008.
3. Mukaro, V., M. Costabile, K. J. Murphy, C. S.T. Hii, P. R.C. Howe and A. Ferrante. Effect of long term consumption of omega-3 enriched foods on circulatory leukocyte numbers and function: Selective depression of natural killer

cell levels. 37th Annual Scientific Meeting of Australasian Society for Immunology Sydney, Australia, December 3-6, 2007.

## **Awards**

Australasian Society for Immunology (ASI) student travel bursary- 2007

Faculty of Health Sciences Postgraduate Travelling Fellowship- 2008



**Abbreviations**

ACTH	adenocortiotropic hormone
ADAM	a disintegrin and matrix metalloprotease domains
APC	antigen presenting cells
AREs	adenosine-uridine rich elements
ASK1	apoptosis signal-regulating kinase
A-SMase	acid sphingomyelinase
ATF	activation transcription factors
BAL	bronchoalveolar lavage
CAMS	cell adhesion molecules
CAPK	ceramide-activated protein kinase
cIAP	cellular inhibitor of apoptosis protein
CINC	cytokine-induced neutrophil chemoattractant
CM	cerebral malaria
COPD	chronic obstructive pulmonary disease
COX	cyclo-oxygenases
CR	complement receptor
CRD	cysteine rich domains
DC	dendritic cells
DC-SIGN	DC specific-ICAM-3-grabbing non-integrin
DD	death domain
DED	death effector domain
DISC	death-inducing signal complex
DMEM	Dulbecco's Modified Eagle's Medium

DTH	delayed-type hypersensitivity
EPO	erythropoietin
ERK	extracellular-signal-regulated kinases
FAD	flavin adenine nucleotide
FADD	Fas-associated death domain
FAN	factor associated with N-SMase activation
FCS	foetal calf serum
FLICE	FADD-like ICE
fMLP	formyl-methionine-leucine-phenylalanine
FSH	follicle stimulating hormone
GAPDH	glyceraldehyde-3-phosphate dehydrogenase
GCK	germinal centre kinase
GH	growth hormone
GM-CSF	granulocyte-macrophage colony stimulating factor
GRO $\alpha$	growth-related gene product
HBSS	Hanks' Balanced salt solution
HF	heart failure
HSP	heat shock proteins
HUVECs	human umbilical vein endothelial cells
ICAM	intracellular-adhesion-molecule
IFN $\gamma$	interferon gamma
IgG	immunoglobulins
I $\kappa$ B	inhibitor kappa B
IKK	I $\kappa$ B kinase

IL	interleukin
IP	interferon- $\gamma$ -inducible protein
ITAMS	immunoreceptor tyrosine-based activation motifs
JNK	c-Jun NH <sub>2</sub> -terminal kinase
KC	keratinocyte chemoattractant
LIF	leukaemia inhibitory factor
LOX	lipoxygenases
LPS	lipopolysaccharide
LT	lymphotoxin
LTBI	latent tuberculosis infection
MAPK	mitogen activated protein kinase
MCP	monocyte chemotactic protein
M-CSF	macrophage CSF
MEF2C	myocyte enhancing factor 2C
MEKK1	MAPK kinase kinase
MHC	major histocompatibility complex
MIP	macrophage inflammatory protein
MMP	matrix metalloproteinase
MNL	mononuclear cells
MPO	myeloperoxidase
MPS	mononuclear phagocyte system
mTNF	membrane bound TNF
mTOR	mammalian target of rapamycin
NADPH	nicotinamide adenine nucleotide phosphate

NEMO	NF- $\kappa$ B essential modulator
NF- $\kappa$ B	nuclear factor kappa B
NIK	NF- $\kappa$ B inducing kinase
NK	natural killer cells
NOS	nitric oxide synthase
NSD	neutral sphingomyelinase domain
N-SMase	neutral sphingomyelinase
PAMPs	pathogen-associated molecular patterns
PDK1	phosphoinositide dependent kinase
PECAM-1	platelet endothelial adhesion molecule-1
PI	3'-phosphoinositide
PI3K	phosphatidylinositol-3-kinase
PLAD	pre-ligand assembly domain
PRR	pattern recognition receptors
RA	rheumatoid arthritis
RIP	receptor interacting protein
ROS	reactive oxygen species
RPMI	Roswell Park Memorial Institute
S1P	sphingosine-1-phosphate
SLE	systemic lupus erythematosus
SMase	sphingomyelinase
SODD	silencer of death domain
SphK	sphingosine kinases
SRBC	sheep red blood cell

STAT	signal transduction and activators of transcription
T regs	regulatory T cells
TACE	TNF $\alpha$ converting enzyme
TANK	TRAF-associated NF- $\kappa$ B activator
TGF $\alpha$	transforming growth factor alpha
TLR	toll-like receptors
TMB	3',3',5',5'-tetramethylbenzidine
TNF	tumour necrosis factor
TNF-RM	TNF rich medium
TNFR I	TNF receptor I
TNFR II	TNF receptor II
TPO	thrombopoietin
TRADD	TNF receptor-associated death domain
TRAF2	TNF receptor associated factor 2
TSH	thyroid stimulating hormone
VEGF	vascular endothelial growth factor

## Index of Figures

Figure 1.1	Relationship between innate and adaptive immunity.....	6
Figure 1.2	The components and activation of the NADPH oxidase.....	18
Figure 1.3	Origin and activation of macrophages.....	25
Figure 1.4	“Good versus Evil”: TNF, a critical component of effective immune surveillance and immunity also promotes a wide range of inflammatory diseases.....	43
Figure 1.5	Signalling pathways activated by TNFR1 and TNFR2.....	49
Figure 1.6	The location of TNF <sub>70-80</sub> and TNF <sub>132-150</sub> within the TNF structure (monomer). .....	77
Figure 3.1	Inability of TNF <sub>70-80</sub> to stimulate p38 activation in cells lacking TNFR.....	105
Figure 3.2	Estimation of TNF <sub>70-80</sub> binding affinity using a simple microtitre-plate based competition binding. ....	106
Figure 3.3.	Lack of effect of control peptide on the binding of biotin-labelled TNF <sub>70-80</sub> to immobilised rHusTNFR1.....	107
Figure 4.1	Activation of NFκB by TNF and TNF <sub>70-80</sub> in human neutrophils. ....	112
Figure 4.2	TNF <sub>70-80</sub> stimulates p38 activity via TRAF2.....	114
Figure 4.3	Lack of activation of GSK3β by TNF <sub>70-80</sub> . ....	117
Figure 4.4	Lack of activation of IKK-α by TNF <sub>70-80</sub> .....	118
Figure 4.5	The effect of peptides TNF <sub>70-80</sub> and TNF <sub>132-150</sub> on superoxide (chemiluminescence) production in neutrophils. ....	120
Figure 4.6	The cytotoxic effect of TNF on WEHI- 164 fibrosarcoma cells. ....	121
Figure 4.7	The cytotoxic effect of TNF <sub>132-150</sub> on WEHI- 164 fibrosarcoma cells.....	122
Figure 4.8	Activation of JNK by TNF <sub>132-150</sub> in WEHI-164 cells.....	123
Figure 4.9	ERK1/ERK2 activation by TNF <sub>132-150</sub> in WEHI-164 cells .....	124
Figure 4.10	Lack of effect of TNF <sub>132-150</sub> on p38 kinase activity in WEHI-164 cells.....	125
Figure 4.11	Differential coupling of TNFR1 to downstream signalling pathways by TNF and TNF <sub>70-80</sub> . ....	127
Figure 5.1	Diagrammatic generation of TNFR1 mutants. ....	132

Figure 5.2	p38 activation in cells transfected with WT or mutant TNFRI .....	133
Figure 5.3	Diagrammatic representation of generation of TNFRI-derived peptides.....	134
Figure 5.4	Kinetics of TNF <sub>70-80</sub> -induced superoxide (chemiluminescence) production from neutrophils in the presence of varying concentrations of TNFRI fragment HM4. ....	136
Figure 5.5	The effect of his-tagged TNFRI fragment- HM4 on TNF <sub>70-80</sub> -induced superoxide (chemiluminescence) production in neutrophils.....	137
Figure 5.6	Kinetics of TNF <sub>70-80</sub> -induced superoxide (chemiluminescence) production from neutrophils in the presence of varying concentrations of TNFRI fragment -HM4. ....	139
Figure 5.7	The effects of TNFRI fragment -HM4 on TNF <sub>70-80</sub> -induced superoxide (chemiluminescence) production in neutrophils.....	140
Figure 5.8	The effects of TNFRI <sub>209-211</sub> on TNF-induced superoxide (chemiluminescence) production in neutrophils. ....	143
Figure 5.9	Comparison of the effects of TNFRI <sub>209-211</sub> and a control peptide on TNF-induced superoxide (chemiluminescence) production in neutrophils. ....	144
Figure 5.10	The effects of TNFRI <sub>206-211</sub> on TNF-induced superoxide (chemiluminescence) production in neutrophils .....	146
Figure 5.11	The effects of TNFRI <sub>206-211</sub> and control peptide on TNF-induced superoxide (chemiluminescence) production in neutrophils.....	147
Figure 5.12	Neutrophil stimulating activities of TNF-rich medium and control medium on neutrophil superoxide (chemiluminescence) production. ....	149
Figure 5.13	Effect of TNFRI <sub>206-211</sub> on TNF-RM-induced superoxide (chemiluminescence) production in neutrophils. ....	150
Figure 5.14	Effect of receptor peptide TNFRI <sub>209-211</sub> on TNF-RM-induced superoxide (chemiluminescence) production in neutrophils.....	151
Figure 5.15	Effect of TNFRI <sub>209-211</sub> on fMLP-induced superoxide (chemiluminescence) generation in neutrophils.....	153
Figure 5.16	Effect of TNFRI <sub>206-211</sub> on the fMLP-induced superoxide (chemiluminescence) generation in neutrophils.....	154
Figure 5.17	Kinetics of p38 activation in neutrophils following stimulation with TNF. ....	157

Figure 5.18	Inhibition of TNF-induced p38 activation in neutrophils by TNFRI peptides. ....	158
Figure 5.19	The effect of TNFRI <sub>206-211</sub> on TNF-induced p38 activation in Mono Mac 6 cells....	159
Figure 5.20	The effect of TNFRI <sub>206-211</sub> on (A) Basal levels of CD11b expression and (B) TNF stimulated up-regulation of neutrophil CD11b expression.....	161
Figure 5.21	The effect of the scrambled control peptide on (A) Basal levels of CD11b expression and (B) TNF stimulated up-regulation of neutrophil CD11b expression. ....	162
Figure 5.22	The effects of TNFRI <sub>206-211</sub> on TNF induced up-regulation of neutrophil CD11b expression in neutrophils. ....	163
Figure 5.23	The effect of TNF on IL-1 $\beta$ expression in neutrophils .....	166
Figure 5.24	Kinetics of IL-1 $\beta$ expression in TNF-stimulated neutrophils. ....	167
Figure 5.25	The effect of TNFRI <sub>206-211</sub> on TNF-induced IL-1 $\beta$ mRNA in neutrophils. ....	168
Figure 5.26	The effect of TNF on IL-8 expression in neutrophils. ....	169
Figure 5.27	Kinetics of IL-8 expression in TNF-stimulated neutrophils. ....	170
Figure 5.28	The effect of TNFRI <sub>206-211</sub> on the production of TNF-induced IL-8 mRNA in neutrophils. ....	171
Figure 5.29	Effect of D-amino form of TNFRI <sub>206-211</sub> on TNF-induced superoxide (chemiluminescence) production.....	174
Figure 5.30	Effect of TNFRI <sub>198-211</sub> on TNF-induced superoxide (chemiluminescence) production. ....	175
Figure 5.31	Effect of a tandem repeat form of TNFRI <sub>209-211</sub> on TNF-induced superoxide (chemiluminescence) production.....	176
Figure 6.1	Effect of TNFRI <sub>206-211</sub> on total leukocyte infiltration in response to LPS.....	184
Figure 6.2	Photomicrographs of peritoneal exudate preparation for the effects TNFRI <sub>206-211</sub> on LPS-induced acute peritonitis. ....	185
Figure 6.3	Effect of TNFRI <sub>206-211</sub> on the accumulation of neutrophils in the peritoneal cavity induced by LPS.....	186
Figure 6.4	Effect of TNFRI <sub>206-211</sub> on the accumulation of macrophages induced by LPS.....	187
Figure 6.5	The effect of TNFRI <sub>206-211</sub> on carrageenan-induced paw inflammation. ....	189



<b>Figure 6.6</b>	<b>The effect of local application of TNFRI<sub>206-211</sub> on carrageenan-induced paw inflammation.....</b>	<b>190</b>
<b>Figure 6.7</b>	<b>The effect of local application of TNFRI<sub>206-211</sub> on DTH response to SRBC.....</b>	<b>192</b>
<b>Figure 7.1</b>	<b>Diagrammatic representation of coupling of TNF<sub>70-80</sub> to TNFRI and associated adaptor proteins and the inferred coupling of TNF<sub>132-150</sub>.....</b>	<b>201</b>

## Index of Tables

<b>Table 1.1</b>	<b>Neutrophil functional receptors.....</b>	<b>12</b>
<b>Table 1.2</b>	<b>Neutrophil granules and constituents.....</b>	<b>15</b>
<b>Table 1.3</b>	<b>Cytokines produced by neutrophils.....</b>	<b>21</b>
<b>Table 1.4</b>	<b>Classification of cytokines based on major functional activities.....</b>	<b>34</b>
<b>Table 1.5</b>	<b>Summary of the biological effects of TNF.....</b>	<b>42</b>
<b>Table 1.6</b>	<b>Inhibitors of TNF in current clinical use .....</b>	<b>66</b>
<b>Table 1.7</b>	<b>Anti-TNF based therapies in various diseases .....</b>	<b>67</b>
<b>Table 1.8</b>	<b>Summary of human clinical studies with p38 inhibitors .....</b>	<b>72</b>
<b>Table 1.9</b>	<b>Comparison of the biological effects of TNF, TNF<sub>70-80</sub> and TNF<sub>132-150</sub>.....</b>	<b>76</b>
<b>Table 2.1</b>	<b>Primer sequences .....</b>	<b>98</b>
<b>Table 5.1</b>	<b>Summary of biological activities of TNFRI-derived peptides .....</b>	<b>177</b>
<b>Table 7.1</b>	<b>Inhibition of TNF-induced superoxide production by TNFRI-derived peptides in neutrophils .....</b>	<b>208</b>